Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care.

Haemophilia : the official journal of the World Federation of Hemophilia·2008
Same author

A review of research related to blood transfusion in Canada, 2000-2002.

Transfusion medicine (Oxford, England)·2004
Same author

Home management of haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2004
Same author

Discrepancies in measured factor VIII activity in patients treated with factor VIII concentrate of human or porcine origin.

Thrombosis and haemostasis·2002
Same author

Health-related quality-of-life treatments for severe haemophilia: utility measurements using the Standard Gamble technique.

Haemophilia : the official journal of the World Federation of Hemophilia·2002
Same author

Unexpected bleeding disorders.

Hematology. American Society of Hematology. Education Program·2001
Same journal

Impact of virtual case conferences between primary care clinicians and an interdisciplinary chronic pain clinic.

Canadian family physician Medecin de famille canadien·2026
Same journal

Canadian family physician Medecin de famille canadien·2026
Same journal

Predictors of high-performing family medicine clinics: Prospective cohort study in Alberta.

Canadian family physician Medecin de famille canadien·2026
Same journal

Acetylsalicylic acid use for artial fibrillation and bleeding risk.

Canadian family physician Medecin de famille canadien·2026
Same journal

Clinical practice guidelines: Important tools to teach the art of medicine.

Canadian family physician Medecin de famille canadien·2026
Same journal

Paratonia in advanced dementia: Challenges and evidence-based interventions.

Canadian family physician Medecin de famille canadien·2026
See all related articles

Related Experiment Video

Updated: Jun 4, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Anticoagulant therapy.

J M Teitel

    Canadian Family Physician Medecin De Famille Canadien
    |February 1, 2011
    PubMed
    Summary
    This summary is machine-generated.

    Venous thromboembolic diseases are a major health concern. Prophylactic treatment with heparin and vitamin K antagonists offers optimal prevention of serious outcomes and complications in high-risk patients.

    More Related Videos

    In Vitro Thrombosis Test for Ventricular Assist Devices
    09:15

    In Vitro Thrombosis Test for Ventricular Assist Devices

    Published on: March 21, 2025

    Related Experiment Videos

    Last Updated: Jun 4, 2026

    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
    23:33

    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

    Published on: February 28, 2012

    In Vitro Thrombosis Test for Ventricular Assist Devices
    09:15

    In Vitro Thrombosis Test for Ventricular Assist Devices

    Published on: March 21, 2025

    Area of Science:

    • Medical research
    • Pharmacology
    • Cardiovascular medicine

    Background:

    • Venous thromboembolic diseases are significant causes of morbidity and mortality in Canada.
    • Effective treatments exist but carry risks of hemorrhagic complications.
    • Prophylactic treatment is crucial for high-risk patients to balance outcomes and complications.

    Purpose of the Study:

    • To review the pharmacology of key antithrombotic agents.
    • To present a rational clinical approach for their use.
    • To optimize the prevention of venous thromboembolic diseases and treatment complications.

    Main Methods:

    • Review of existing literature on heparin and vitamin K antagonists.
    • Analysis of pharmacological properties and clinical applications.
    • Synthesis of evidence to guide prophylactic treatment strategies.

    Main Results:

    • Heparin and vitamin K antagonists are mainstays of antithrombotic therapy.
    • Understanding their pharmacology is key to effective use.
    • Prophylaxis in high-risk patients can mitigate serious outcomes and complications.

    Conclusions:

    • Antithrombotic agents are vital for managing venous thromboembolic diseases.
    • A rational, evidence-based approach to their clinical use is essential.
    • Prophylactic strategies are critical for improving patient safety and treatment efficacy.